$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000161883520000047 Filed on March 12, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2018 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.00M	$9.440M	$5.210M
YoY Change	161.14%	81.19%	157.92%
% of Gross Profit
Research & Development	$4.247M	$3.430M	$9.770M
YoY Change	-46.17%	-64.89%	2691.43%
% of Gross Profit
Depreciation & Amortization	$70.00K	$60.00K	$60.00K
YoY Change	0.0%	0.0%	200.0%
% of Gross Profit
Operating Expenses	$19.24M	$12.87M	$14.98M
YoY Change	41.17%	-14.08%	-2.38%
Operating Profit	-$19.24M
YoY Change	41.17%
Interest Expense	$0.00	$120.0K	$30.00K
YoY Change	-100.0%	300.0%	200.0%
% of Operating Profit
Other Income/Expense, Net	$98.00K	$155.0K	$0.00
YoY Change	-102.21%		-100.0%
Pretax Income	-$19.15M	-$12.72M	-$14.98M
YoY Change	5.97%	-15.09%	534.75%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$19.15M	-$12.72M	-$14.98M
YoY Change	5.97%	-15.11%	-23.15%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$397.3K	-$251.2K	-$579.3K
COMMON SHARES
Basic Shares Outstanding	49.59M shares	46.81M shares	25.87M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q4	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.40M	$23.80M	$1.300M
YoY Change	5100.0%	1730.77%	-61.76%
Cash & Equivalents	$8.785M	$15.57M	$1.330M
Short-Term Investments	$1.600M	$8.200M
Other Short-Term Assets	$3.000M	$1.900M	$700.0K
YoY Change	200.0%	171.43%	16.67%
Inventory		$0.00
Prepaid Expenses
Receivables		$0.00
Other Receivables
Total Short-Term Assets	$13.72M	$26.42M	$2.478M
YoY Change	870.77%	966.22%	5.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$622.0K	$394.0K	$593.0K
YoY Change	18.03%	-33.56%	-30.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.044M	$1.320M	$939.0K
YoY Change	60.86%	40.58%	25.2%
Total Long-Term Assets	$1.928M	$1.874M	$1.532M
YoY Change	5.88%	22.32%	-4.13%
TOTAL ASSETS
Total Short-Term Assets	$13.72M	$26.42M	$2.478M
Total Long-Term Assets	$1.928M	$1.874M	$1.532M
Total Assets	$15.65M	$28.30M	$4.010M
YoY Change	383.77%	605.61%	1.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.120M	$6.008M	$8.882M
YoY Change	-40.33%	-32.36%	-1.3%
Accrued Expenses	$2.499M	$2.784M	$11.51M
YoY Change	-78.54%	-75.82%	-4.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$4.000M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.46M	$12.66M	$27.33M
YoY Change	-54.93%	-53.68%	-73.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$200.0K	$0.00	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$200.0K	$0.00	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.46M	$12.66M	$27.33M
Total Long-Term Liabilities	$200.0K	$0.00	$0.00
Total Liabilities	$14.62M	$12.66M	$27.37M
YoY Change	-54.42%	-53.74%	-73.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$532.3M	-$513.2M	-$433.1M
YoY Change	17.97%	18.48%	40.96%
Common Stock	$533.3M	$528.8M	$409.8M
YoY Change	26.28%	29.05%	2211.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.021M	$15.64M	-$23.36M
YoY Change
Total Liabilities & Shareholders Equity	$15.65M	$28.30M	$4.010M
YoY Change	383.77%	605.61%	1.47%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2018 Q4
OPERATING ACTIVITIES
Net Income	-$19.15M	-$12.72M	-$14.98M
YoY Change	5.97%	-15.11%	-23.15%
Depreciation, Depletion And Amortization	$70.00K	$60.00K	$60.00K
YoY Change	0.0%	0.0%	200.0%
Cash From Operating Activities	-$14.88M	-$13.45M	-$10.25M
YoY Change	93.75%	31.22%	334.32%
INVESTING ACTIVITIES
Capital Expenditures	$95.00K	-$140.0K	-$10.00K
YoY Change		1300.0%
Acquisitions
YoY Change
Other Investing Activities	$6.900M	-$4.480M	$0.00
YoY Change	2660.0%
Cash From Investing Activities	$6.902M	-$4.630M	-$10.00K
YoY Change	2660.8%	46200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.364M	2.200M	-500.0K
YoY Change	-78.24%	-540.0%	-1766.67%
NET CHANGE
Cash From Operating Activities	-$14.88M	-13.45M	-10.25M
Cash From Investing Activities	$6.902M	-4.630M	-10.00K
Cash From Financing Activities	$1.364M	2.200M	-500.0K
Net Change In Cash	-$6.610M	-15.88M	-10.76M
YoY Change	469.34%	47.58%	361.8%
FREE CASH FLOW
Cash From Operating Activities	-$14.88M	-$13.45M	-$10.25M
Capital Expenditures	$95.00K	-$140.0K	-$10.00K
Free Cash Flow	-$14.97M	-$13.31M	-$10.24M
YoY Change		29.98%	333.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1300000	USD
CY2019Q2	dei	Entity Public Float EntityPublicFloat	42898789	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	9153000	USD
CY2019Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	585000	USD
CY2018Q4	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	174000	USD
CY2019Q4	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	0	USD
CY2018Q4	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1117000	USD
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49594477	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q4	evfm	Accrued Sublicense Fees AccruedSublicenseFees	0	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationOfPurchaseRightsLiability	22800000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Warrants AdjustmentsToAdditionalPaidinCapitalReclassificationOfWarrants	6900000	USD
CY2019	evfm	Adjustments To Additional Paidin Capital Reclassificationof Warrants And Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationofWarrantsAndPurchaseRightsLiability	29726000	USD
CY2018Q2	evfm	Class Of Warrant Or Right Issued In Transaction ClassOfWarrantOrRightIssuedInTransaction	8500000	shares
CY2019Q4	evfm	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	5305377	shares
CY2019Q4	evfm	Common Stock Reserved Upon Release Of Restricted Stock Units CommonStockReservedUponReleaseOfRestrictedStockUnits	81667	shares
CY2019Q2	evfm	Compensation Agreement Potential Bonus As A Percent Of Consulting Fees Earned CompensationAgreementPotentialBonusAsAPercentOfConsultingFeesEarned	1
CY2018	evfm	Deemed Contribution Upon Exchange Of Preferred Stock DeemedContributionUponExchangeOfPreferredStock	49334000	USD
CY2018	evfm	Deferred Rent Adjustment DeferredRentAdjustment	242000	USD
CY2019	evfm	Deferred Rent Adjustment DeferredRentAdjustment	0	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.05
CY2018	evfm	Effective Income Tax Rate Reconciliation Accrual Of Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationAccrualOfUncertainTaxPositions	-0.0057
CY2019	evfm	Effective Income Tax Rate Reconciliation Accrual Of Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationAccrualOfUncertainTaxPositions	-0.0042
CY2018	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Liquidation Preference EffectiveIncomeTaxRateReconciliationChangeInFairValueOfLiquidationPreference	-0.0002
CY2019	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Liquidation Preference EffectiveIncomeTaxRateReconciliationChangeInFairValueOfLiquidationPreference	0.0000
CY2018	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Purchase Rights Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPurchaseRightsPercent	0.0000
CY2019	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Purchase Rights Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPurchaseRightsPercent	0.0515
CY2018	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0.0000
CY2019	evfm	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	0.0203
CY2019	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	6120000	USD
CY2014Q4	evfm	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized	0.010
CY2018	evfm	Effective Income Tax Rate Reconciliation Deduction Loss On Issuance Of Warrants Percent EffectiveIncomeTaxRateReconciliationDeductionLossOnIssuanceOfWarrantsPercent	0.0801
CY2019	evfm	Effective Income Tax Rate Reconciliation Deduction Loss On Issuance Of Warrants Percent EffectiveIncomeTaxRateReconciliationDeductionLossOnIssuanceOfWarrantsPercent	0.0018
CY2018	evfm	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	0.0003
CY2019	evfm	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	-0.0026
CY2019Q2	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	19600000	USD
CY2018	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	0	USD
CY2019	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	19617000	USD
CY2018	evfm	Financing Costs Included In Accounts Payable And Accrued Expense FinancingCostsIncludedInAccountsPayableAndAccruedExpense	94000	USD
CY2019	evfm	Financing Costs Included In Accounts Payable And Accrued Expense FinancingCostsIncludedInAccountsPayableAndAccruedExpense	306000	USD
CY2018	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0	USD
CY2019	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	761000	USD
CY2019Q2	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	700000	USD
CY2018	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	0	USD
CY2019	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	674000	USD
CY2018	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	47920000	USD
CY2019	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
CY2018Q4	evfm	Notes Issued Stated Rate Monthly Percent Of Principal Permitted NotesIssuedStatedRateMonthlyPercentOfPrincipalPermitted	0.01
CY2018Q2	evfm	Number Of Funds NumberOfFunds	3	fund
	evfm	Number Of Sublicenses NumberOfSublicenses	2	Agreement
CY2015Q1	evfm	Operating Leases Number Of Renewal Options For Extended Terms OperatingLeasesNumberOfRenewalOptionsForExtendedTerms	2	renewal_term
	evfm	Periodic Release Of Security Deposit PeriodicReleaseOfSecurityDeposit	5000	USD
CY2018	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	37542000	USD
CY2019	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2019	evfm	Proceeds From Issuance Of Common Stock Net Of Commissions ProceedsFromIssuanceOfCommonStockNetOfCommissions	2960000	USD
CY2019Q2	evfm	Purchase Right Liability PurchaseRightLiability	3200000	USD
CY2019	evfm	Stock Issued During Period Shares Employee Stock Purchase Plans And Exercise Of Stock Options StockIssuedDuringPeriodSharesEmployeeStockPurchasePlansAndExerciseOfStockOptions	88074	shares
CY2019	evfm	Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions	392000	USD
CY2019Q4	evfm	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	7100000	USD
CY2019Q2	evfm	Warrant Liability WarrantLiability	3600000	USD
CY2018	evfm	Warrants And Stock Issued During Period Value New Issues WarrantsAndStockIssuedDuringPeriodValueNewIssues	14062000	USD
CY2019	evfm	Weighted Average Remaining Period WeightedAverageRemainingPeriod	P2Y0M7D
CY2019Q4	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	13800000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8882000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6008000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11513000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2784000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	549000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1652000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	604000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	849000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	409787000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	528810000	USD
CY2018	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-1592000	USD
CY2019	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-1566000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15571000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15600000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1701000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1761000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16625000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	60000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14864000	USD
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25867248	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48137880	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2017Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	80	shares
CY2018	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	80000000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17842000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8579000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17842000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8579000	USD
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10543513	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11966220	shares
CY2019Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	24474	sqft
CY2018Q4	us-gaap	Assets Assets	4010000	USD
CY2019Q4	us-gaap	Assets Assets	28295000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	2478000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	26421000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	904000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	22588000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
CY2018	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1900000	USD
CY2019	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1330000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.60
CY2018Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.50
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5305377	shares
CY2018Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	848874	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12750022	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25867248	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48137880	shares
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.99
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000000000000000138777878078145
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1283
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3905000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3367000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	885000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	37000	USD
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	53933000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	62955000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	672000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	591000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	65205000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	74751000	USD
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5948000	USD
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6953000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	747000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	65205000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74717000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	34000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.030
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	262000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	263000	USD
CY2018	us-gaap	Depreciation Nonproduction DepreciationNonproduction	300000	USD
CY2019	us-gaap	Depreciation Nonproduction DepreciationNonproduction	300000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2017Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	5200000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.62
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.74
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1205
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0056
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0205
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0103
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0058
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0019
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0021
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0037
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0160
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0135
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2924000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3670000	USD
CY2019Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3300000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7755000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-79000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34227000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30512000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	42000	USD
CY2018Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	0	USD
CY2019Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	8233000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	8275000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-125670000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-80029000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-125710000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-80029000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-40000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-125710000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-80029000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	4000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54417000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27329000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12659000	USD
CY2018	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-130000	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2019Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3799000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2931000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-795000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-8775000	USD
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	307000	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	746000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	952000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	127000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	458000	USD
CY2018	us-gaap	Lease Cost LeaseCost	0	USD
CY2019	us-gaap	Lease Cost LeaseCost	642000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2019Q4	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Renewal Term1 LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1	P5Y
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	201000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4000	USD
CY2015Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P0Y3M
CY2018Q4	us-gaap	Liabilities Liabilities	27366000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	12659000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4010000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28295000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78076000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2143000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8115000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56500000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55097000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-69056000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-23244000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-18431000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-14981000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-125712000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-18068000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-35450000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-13798000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-12717000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-80033000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-69122000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23244000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18431000	USD
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14981000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-52742000	USD
CY2018	us-gaap	Operating Lease Cost OperatingLeaseCost	578000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-125778000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18068000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35450000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13798000	USD
CY2019Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12717000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-80033000	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	46000	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-48070000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2000	USD
CY2018Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-48068000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4436000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23505000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-499000	USD
CY2019Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	155000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27287000	USD
CY2018Q4	us-gaap	Notes Issued1 NotesIssued1	4000000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4010000	USD
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	20986000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	23242000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	18433000	USD
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	14981000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	77642000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	13632000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	11941000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	14297000	USD
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	12872000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	52742000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-77642000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	737000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	200000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	197000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	197000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	834000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	160000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	978000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	777000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	520000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	547000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	939000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	201000	USD
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1197000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1243000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	593000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1320000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-145000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	301000	USD
CY2018Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	200000	USD
CY2018	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	157000	USD
CY2019	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
CY2018	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1418000	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1286000	USD
CY2018Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1592000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1566000	USD
CY2018	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
CY2019	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	8233000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	164000	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	717000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2313000	USD
CY2018	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2019	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	20000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	75400000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	42000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	305000	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	32000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	95000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6273000	USD
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4010000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43415000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22230000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	431000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	304000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	431000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	304000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-433146000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-513179000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-513200000	USD
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	802000	USD
CY2019Q4	us-gaap	Security Deposit SecurityDeposit	750000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	17842000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	8579000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.870
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.763
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.029
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.15
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	28333	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	133000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.99
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.50
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.58
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.94
CY2018	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	416000	USD
CY2019	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	40335	shares
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	121315000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	5226000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-289546000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-23356000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15636000	USD
CY2018	us-gaap	Stockholders Equity Change In Reporting Entity StockholdersEquityChangeInReportingEntity	1946000	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	166.7000
CY2018	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	223000	USD
CY2018	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	66000	USD
CY2019	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1335000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2061000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2413000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	564000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	352000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	162000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2018Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	14100000	USD
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21900574	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40228517	shares
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto. </font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">S</font><font style="font-family:inherit;font-size:10pt;">ignificant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but not limited to: the discount rate used in estimating the fair value of the lease right-of-use (ROU) assets and lease liabilities, the measurement of the Series D 2X liquidation preference, assumptions used in estimating the fair value of warrants and Purchase Rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, and assumptions used in estimating the fair value of stock-based compensation expense. The Company’s assumptions regarding the measurement of the First Closing Warrants, the Purchase Rights, the Series D 2X liquidation preference, the lease ROU assets and lease liabilities, and stock-based compensation are more fully described in </font><a style="font-family:inherit;font-size:10pt;" href="#s496B3063D34E59E1864C4C8DE983431B"><font style="font-family:inherit;font-size:10pt;">Note 5 — Fair Value of Financial Instruments</font></a><font style="font-family:inherit;font-size:10pt;">, </font><a style="font-family:inherit;font-size:10pt;" href="#s8F38B318250258DB8B91BCE8CEBCCC46"><font style="font-family:inherit;font-size:10pt;">Note 6 — Commitments and Contingencies</font></a><font style="font-family:inherit;font-size:10pt;">, and </font><a style="font-family:inherit;font-size:10pt;" href="#s12B298797D3151D79BC693D3ABC7DB6A"><font style="font-family:inherit;font-size:10pt;">Note 12 — Stock-based Compensation</font></a><font style="font-family:inherit;font-size:10pt;">, respectively. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001618835-20-000047-index-headers.html	Edgar Link	pending
0001618835-20-000047-index.html	Edgar Link	pending
0001618835-20-000047.txt	Edgar Link	pending
0001618835-20-000047-xbrl.zip	Edgar Link	pending
evfm-1231201910xk.htm	Edgar Link	pending
evfm-12312019ex105810k.htm	Edgar Link	pending
evfm-12312019ex23110k.htm	Edgar Link	pending
evfm-12312019ex31110k.htm	Edgar Link	pending
evfm-12312019ex31210k.htm	Edgar Link	pending
evfm-12312019ex32110k.htm	Edgar Link	pending
evfm-12312019ex41510k.htm	Edgar Link	pending
evfm-20191231.xml	Edgar Link	completed
evfm-20191231.xsd	Edgar Link	pending
evfm-20191231_cal.xml	Edgar Link	unprocessable
evfm-20191231_def.xml	Edgar Link	unprocessable
evfm-20191231_lab.xml	Edgar Link	unprocessable
evfm-20191231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image2a26.jpg	Edgar Link	pending
image3a27.jpg	Edgar Link	pending
newcontraceptivetable.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2020 Q1 Form 10-K Financial Statement

#000161883520000047 Filed on March 12, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2020 Q1 Form 10-K Financial Statement

#000161883520000047 Filed on March 12, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm